# ModernaTX, Inc.: Phase 2 study completed, 1407 enrolled (Norovirus Acute Gastroenteritis)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age |
| NCT ID | NCT05992935 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Norovirus Acute Gastroenteritis |
| Intervention types | biological |
| Target enrollment | 1407 |
| Site countries | United States, Australia |
| Posted | 2023-08-15 |
| Planned start | 2023-08-25 |
| Event | Completed |
| Event date | 2026-10-07 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 1407 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05992935). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.